Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Sonal Shad, William Fraser Symmans, Debu Tripathy, Lamorna Brown-Swigart, LJ Esserman, Jane Perlmutter, V. Valero, Rebekah Gould, Gregor Krings, Judy C. Boughey, Jodi M. Carter, M. van der Noordaa, Gillian L. Hirst, L.J. van 't Veer, Christina Yau, Douglas Yee, Lajos Pusztai, Tufia C. Haddad, Kathy S. Albain, Molly Klein, Lili Du, MC Liu, Rita Nanda, Claudine Isaacs, Richard Schwab, Amy Jo Chien, Donald A. Berry, Rachel M. Layman, AM DeMichele, Isabelle Bedrosian, Sara J. Venters, Nola M. Hylton
Publikováno v:
Annals of Oncology. 32:642-651
BACKGROUND We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should measure transcription related to estrogen and progesterone receptors (SETER/PR in
Autor:
Stephanie Mendez, J. Daniel Cuevas, Gabrielle B. Rocque, Joanne L. Blum, Jennifer M. Specht, Steven W. Corso, Yao Wang, Joseph C. Cappelleri, Jawad E Francis, Debu Tripathy, Veneta Pope
Publikováno v:
Cancer Research. 81:SS2-10
Background: The COVID-19 pandemic is negatively affecting patient enrollment, therapy administration, and patient visits in breast cancer clinical trials worldwide. COVID-19 may have a lasting impact on how clinical trials are conducted, and guidelin
Autor:
Akshara Singareeka Raghavendra, Katherine Clifton, Min Yi, Debu Tripathy, Jennifer K. Litton, Meghan Sri Karuturi
Publikováno v:
Cancer Research. 80:P5-11
Background: CDK 4/6 inhibitors have become frontline treatment for patients (pts) with advanced hormone receptor (HR) positive breast cancer. There is limited data regarding post-progression outcomes in pts receiving CDK 4/6 inhibitors as standard of
Autor:
Marco Colleoni, Arunava Chakravartty, Sara A. Hurvitz, Rafael Villanueva-Vazquez, Aditya Bardia, Louis W.C. Chow, Kyung Hae Jung, Gareth Hughes, Joohyuk Sohn, Tetiana Taran, Ioannis Gounaris, Saúl Campos-Gómez, Seock-Ah Im, Keun-Seok Lee, Fabio Franke, Karen Rodriguez-Lorenc, Nadia Harbeck, Yen-Shen Lu, Debu Tripathy
Publikováno v:
New England Journal of Medicine. 381:307-316
Background An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with r...
Autor:
Sandra M. Swain, Vincent Antao, Haocheng Li, Debu Tripathy, Joyce O'Shaughnessy, Laura Chu, Ginny Mason, Peter A. Kaufman, Denise A. Yardley, Sara A. Hurvitz, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Melody A. Cobleigh
Publikováno v:
The oncologist, vol 25, iss 2
The Oncologist
The Oncologist
Background Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). Materials and Methods The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f85b6f5b4b0427599690acf0ecde9c9
https://escholarship.org/uc/item/3141135z
https://escholarship.org/uc/item/3141135z
Autor:
Jennifer K. Litton, NT Ueno, V. Valero, Debu Tripathy, Senthil Damodaran, Richard B. Lanman, Victoria M. Raymond, S. L. Moulder, I. I. Wistuba, Stanley R. Hamilton, KR Hess, Funda Meric-Bernstam
Publikováno v:
Cancer Research. 79:OT1-03
Background Mutations in the ligand-binding domain of ESR1 have been demonstrated to mediate resistance to aromatase inhibitors (AI) and are associated with poor survival. Analyses of circulating tumor DNA (ctDNA) offer a minimally invasive and real-t
Autor:
Debu Tripathy, Matthew P. Goetz, Daniel F. Hayes, Matthew J. Ellis, Melody A. Cobleigh, Ron Bose, Carey K. Anders, Michael Naughton, Shana Thomas, Eric P. Winer, Alshad S. Lalani, Jill Anderson, Melinda L. Telli, Rachel A. Freedman, Cynthia X. Ma, Gretchen Kimmick, P. Bedard, Richard B. Lanman, Timothy J. Pluard, Christy A. Russell, Kimberly L. Blackwell, Feng Gao, Caroline Bumb, Andres Forero, John D. Pfeifer, Mark D. Pegram, Kimberly C. Banks, Richard Bryce, Polly A. Niravath, Hussam Al-Kateb
Publikováno v:
Clinical Cancer Research. 23:5687-5695
Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified me
Autor:
Debu Tripathy, Sabine Seiler, Lisa A. Carey, Ian E. Krop, Matthew P. Goetz, S Delalogue, Sherene Loi, E.M. Ciruelos, AM DeMichele, Aleix Prat, Sumithra J. Mandrekar, Kathy D. Miller, Luca Gianni, Elgene Lim, Ines Vaz-Luis, Otto Metzger, PA Francis, S. Loibl, Pinuccia Valagussa, C-S Huang, EP Winer, T Dockter, Christoph Mundhenke, J Lanzillotti
Publikováno v:
Cancer Research. 78:OT3-05
Background Pre-clinical data and initial results from clinical studies point to the added benefit of CDK4/6 inhibition when combined with anti-HER2 tx. The current study is designed to evaluate the added benefit of palbociclib when given in combinati
Autor:
Yi Min, Jaime Kimmel, Debu Tripathy, Jennifer K. Litton, Katherine Clifton, Meghan Sri Karuturi
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Over 40% of newly diagnosed metastatic breast cancer patients are ≥ 70 years-old however this population is less likely to be represented in clinical trials. The objective of this study was to analyze PFS, dose reductions, dose delays and
Trastuzumab (H) with chemotherapy benefits patients with HER2+ breast cancer (BC); however, we lack head-to-head pairwise assessment of survival or cardiotoxicity for specific combinations. We sought to identify optimal combinations. We searched PubM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe91bdfae57694511392f98fb81cd6b9
https://europepmc.org/articles/PMC6538294/
https://europepmc.org/articles/PMC6538294/